antiphospholipid antibodiesantiphospholipid syndromeischemic strokeyoung adultsSneddon’s syndromeантитела к фосфолипидамантифосфолипидный синдромишемический инсультмолодой возрастсиндром СнеддонаДобрынина Л.А., Калашникова Л.А., Павлова Л.Н. Причины ишемического инсульта в молодом возрасте. Журнал неврологии и психиатрии им. С.С. Корсакова. В печати.Калашникова Л.А. Неврология антифосфолипидного синдрома. М.: Медицина, 2003.Калашникова Л.А. Неишемические неврологические проявления у больных с первичным антифосфолпидным синдромом (опыт собственных 16-летних исследований). Журнал неврологии и психиатрии им. С.С. Корсакова 2005; 105 (2): 18–23.Калашникова Л.А. Первичный антифосфолипидный синдром и нарушения мозгового кровообращения. Журнал неврологии и психиатрии им. С.С. Корсакова 2005; 105 (5): 11–16.Калашникова Л.А., Бодарева Э.А., Кашина Е.М. и др. Нарушение высших психических функций и деменция при синдроме Снеддона. Неврологический журнал 1998; 4: 15–18.Калашникова Л.А., Добрынина Л.А., Александрова Е.Н. и др. Антитела к фосфолипидам и синдром Снеддона. Нейроиммунология. Материалы XII Всероссийской конференции. Санкт-Петербург 2003; 63.Калашникова Л.А., Насонов Е.Л., Александрова Е.Н. и др. Антитела к фосфолипидам и ишемические нарушения мозгового кровообращения в молодом возрасте. Журнал неврологии и пси- хиатрии им. С.С. Корсакова 1997; 6: 59–65.Калашникова Л.А., Насонов Е.Л., Александрова Е.Н. и др. Ишемические нарушения мозгового кровообращения и пораже- ния клапанов сердца при первичном антифосфолипидном син- дроме. Клин. мед. 1996; 6: 46–49.Калашникова Л.А., Насонов Е.Л., Кушекбаева А.Е., Грачева Л.А. Синдром Снеддона (связь с антителами к кардиолипину). Клин. мед. 1988; 10: 32–37.Калашникова Л.А., Стоянович Л.З., Насонов Е.Л., Ковалев В.Ю. Дифференциальный диагноз синдрома Снеддона и системной красной волчанки с проявлениями антифосфолипидного син- дрома. Клин. ревматология 1993; 1: 22–26.Ложникова С.М., Сахарова Л.В., Калашникова Л.А., Людковская И.Г. Морфологические изменения в коже и поверхностных височных артериях при синдроме Снеддона. Архив пат. 1991; 1: 47–52.Asherson R.A., Mercey D., Phillips G. et al. Recurrent stroke and multi-infarct dementia in systemic lupus erythematosus: association with antiphospholipid antibodies. Ann. Rheum. Dis. 1987; 46: 605–611. ЛЕКЦИЯ Цереброваскулярные нарушения при антифосфолипидном синдромеBrandt J.T., Triplett D.A., Alving B., Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74: 1185–90.Brey R., Hart R., Sherman D. et al. Antiphospholipid antibodies and cerebral ischemia in young people. Neurology 1990; 40: 1190–1196.Cervera R., Boffa M.-C., Khamastha M.A., Hughes G.R.U. The Euro-Phospholipid Project epidemiology of the antiphospholipid syndrome in Europe. Lupus 2009; 18 (Spec No): 889–893.Crowther M.A., Ginsberg J.S., Julian J. et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N. Engl. J. Med. 2003; 349: 1133–1138.Del Papa N., Guidali L., Sala A. et al. Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal antibeta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation. Arthritis Rheum. 1997; 40: 551–561.Finazzi G., Marchioli R., Brancaccio V. et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J. Thromb Haemost. 2005; 3: 848–853.Gharavi A.E., Harris E.N., Asherson R.A., Hughes G.R.V. Anticardiolipin antibodies: isotype distribution and phospholipid specificity. Ann. Rheumatol. Dis. 1987; 46: 1–6.Harris E.N., Gharavi A.E., Boey M.L. et.al. Anticardiolipin antibodies: Detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; 2: 1211–1213.Hoppensteadt D.A., Fabbrini N., Bick R.L. et.al. Laboratory evaluation of the antiphospholipid syndrome. Hematol. Oncol. Clin. North Am. 2008; 22:.19–32.Hughes G.R. Migraine, memory loss, and ‘‘multiple sclerosis.’’ Neurological features of the antiphospholipid (Hughes’) syndrome. Postgrad. Med. J. 2003; 79: 81–83.Hughes G.R.V. Hughes syndrome (the antiphospholipid syndrome) ten clinical lessons. Autoimmun Rev. 2008; 7: 262–266.Kalashnikova L.A., Dobrynina L.A., Nasonov E.L. et al. Sneddon’s syndrome (SS) with antiphospholipid antibodies (aPL) and primary antiphospholipid syndrome (PAPS) with cerebrovascular disease (CVD). J. Autoimmunity 2000; 15(2): 11.Kalashnikova L.A., Nasonov E.L., Kushekbaeva A.E., Gracheva L.A. Anticardiolipin antibodies in Sneddon’s syndrome. Neurology 1990; 40: 464–467.Kalashnikova L.A., Nasonov E.L., Stoyanovich L.Z. еt al. Sneddon’s syndrome and the primary antiphospholipid syndrome. Cerebrovasc. Dis. 1994; 4: 76–82.Kenet G., Sadetzki S., Murad H. еt al. Leiden and antiphospholipid antibodies aresignificant risk factors for ischemic stroke in children. Stroke 2000; 31: 1283–1288.Khamashta M.A., Cuadrado M.J., Mujic F. еt al. The management of thrombosis in the antiphospholipid antibody syndrome. N. Engl. J. Med. 1995; 332: 993–997.Kitagawa Y. Antiphospholipid syndrome and stroke. Rinsho Shinkeigaku 2005; 45: 852–855.Levine S.R., Deegan M.J., Futrell N., Welch K.M.A. Cerebrovascular and neurological disease associated with antiphospholipid antibodies: 48 cases. Neurology 1990; 40: 1181-1189.Levine S.R., Langer S.L., Albers J.W., Welch K.M.A. Sneddon’s syndrome: an antiphospholipid antibody syndrome? Neurology 1988; 38: 798–800.Loizou S., McCrea J.D., Rudge A.C. et al. Measurement of anticardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): standardization and quantitation of results. Clin. Exp. Immunol. 1985; 62: 738–745.Mehdi A.A., Uthman I., Khamashta M. Antiphospholipid syndrome: pathogenesis and a window of treatment opportunities in the future. Eur. J. Clin. Invest. 2010; 40: 451–464.Miyakis S., Lockshin M.D., Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J. Thromb Haemost. 2006; 4: 295–306.Pierangeli S.S., Chen P.P., Raschi E. et al. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin. Thromb Hemost. 2008; 34: 236–250.Rodrigues C.E.M., Carvalho J.F., Shoenfeld Y. Neurological manifestations of antiphospholipid syndrome. Eur. J. Clin. Invest 2010; 40: 350–359.Shoenfeld Y., Nahum A., Korczyn A.D. et al. Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. J. Lupus 2003; 12: 436–442.Sinharay R. Sneddon’s syndrome: additional neurological feature in antiphospholipid (Hughes’) syndrome. Postgrad. Med. J. 2003; 79: 550.Sitzer M., Sohngen D., Siebler M. et al. Cerebral microembolism in patients with Sneddon’s syndrome. Arch. Neurol. 1995; 52: 271–275.Sneddon I.B. Cerebro-vascular lesions and livedo reticularis. Br. J. Dermatol. 1965; 77: 180–185.Toschi V., Motta C., Castelli C. et al. High prevalence of antiphospholipid antibodies in young patients with cerebral ischemia of undetermined cause. Stroke 1998; 29: 1759–1764.Wisloff F., Jacobsen E.M., Liestol S. Laboratory diagnosis of the antiphospholipid syndrome. Thromb Res. 2002; 108: 263–271.Woimant F., Dosquet C., Kubis N. et al. Anticardiolipin antibodies and ischemic stroke in young adults. Cerebrovasc. Dis. 1996; 6: 97.Zelger B., Sepp N., Stockhammer G. et al. Sneddon’s syndrome. A long term follow up of 25 patients. Arch. Dermatol. 1993; 129: 437–447.